Toabo Corporation
3204・Standard Market・Textiles & Apparels
Fine Chemicals
High value-added segment manufacturing and selling electronic materials for semiconductors and pharmaceuticals
| Period | Current | Previous | Change |
|---|---|---|---|
| Net Sales (Q1 FY2026, ending December 2026) | ¥336 million | ¥321 million (Q1 FY2025, ending December 2025) | ↑ |
| Net Sales YoY Change | Up 4.5% | — | ↑ |
| Operating Income (Q1 FY2026, ending December 2026) | ¥12 million | ¥16 million (Q1 FY2025, ending December 2025) | ↓ |
| Operating Margin (Q1 FY2026, ending December 2026) | 3.6% | 5.0% (Q1 FY2025, ending December 2025) | ↓ |
| Operating Income YoY Change | Down 22.7% | — | ↓ |
Business Details
A business that manufactures and sells healthcare-related chemicals, chemicals for electronic materials, and industrial chemicals. In the electronic materials field, the company captures robust demand centered on semiconductor process materials, while in the pharmaceutical field, it handles APIs for generics and other products. In the first quarter of FY2026 (ending December 2026), the electronic materials field performed steadily, resulting in increased sales, while the pharmaceutical field is beginning to show signs of recovery, with increased sales expected from the second quarter onward.
Recent Overview
Electronic materials saw increased sales, but operating income fell 22.7% YoY, indicating declining profitability
In the first quarter of FY2026 (ending December 2026), the electronic materials field saw steady production and sales for semiconductors, resulting in increased sales (net sales of ¥336 million, up 4.5% YoY). Meanwhile, operating income declined 22.7% YoY to ¥12 million, indicating a decline in profitability. The pharmaceutical field is beginning to show signs of recovery, with increased sales expected from the second quarter onward. There is no change to the full-year earnings forecast, and recovery is expected in the second half.
Key Products
Growth Drivers
- Robust demand for electronic materials for semiconductors (market growth driven by expanding AI and semiconductor investment)
- Signs of recovery in the pharmaceutical field and expected increase in sales from the second quarter onward
- Development of high-functionality materials through proprietary technology and creation of customer value
- Continued capacity expansion investment in the electronic materials field
Risks
- Erosion of generic demand due to aggressive marketing of authorized generics (AG) by original brand manufacturers in the pharmaceutical field
- Risk of fluctuation in the semiconductor market (fluctuation in electronic materials demand due to demand cycles)
- Risk of rising raw material prices and procurement difficulties
- Pressure on profitability due to increased depreciation expenses associated with capacity expansion investment
- Risk of competitors entering the high-functionality materials field
Last updated: March 26, 2026